Pacific Biosciences of California Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California or view top-rated stocks.

Wall Street analysts have given Pacific Biosciences of California a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pacific Biosciences of California wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Pacific Biosciences of California.

Pacific Biosciences of California will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) issued its earnings results on Tuesday, February, 9th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by $0.06. The biotechnology company had revenue of $27.10 million for the quarter, compared to analyst estimates of $25.54 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 43.06% and a negative net margin of 64.25%. The company's quarterly revenue was up 41.9% compared to the same quarter last year.
View Pacific Biosciences of California's earnings history.

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PACB stock has increased by 834.6% and is now trading at $32.15.
View which stocks have been most impacted by COVID-19.

Pacific Biosciences of California updated its second quarter 2021 earnings guidance on Tuesday, July, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.50 million-$30.50 million, compared to the consensus revenue estimate of $29.89 million.

4 analysts have issued 12 month target prices for Pacific Biosciences of California's stock. Their forecasts range from $15.00 to $62.00. On average, they expect Pacific Biosciences of California's stock price to reach $43.50 in the next twelve months. This suggests a possible upside of 35.3% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California or view top-rated stocks among Wall Street analysts.

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bio-Techne (TECH), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of PACB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by many different institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.12%), Archford Capital Strategies LLC (0.04%), Carnegie Capital Asset Management LLC (0.02%), Compagnie Lombard Odier SCmA (0.01%) and IFP Advisors Inc (0.00%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California.

PACB stock was acquired by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Carnegie Capital Asset Management LLC, Alliancebernstein L.P., Archford Capital Strategies LLC, and IFP Advisors Inc.
View insider buying and selling activity for Pacific Biosciences of California or or view top insider-buying stocks.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $32.15.

Pacific Biosciences of California has a market capitalization of $6.38 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.43) on an earnings per share basis.

Pacific Biosciences of California employs 147,000 workers across the globe.

Pacific Biosciences of California was founded in 2004.

The official website for Pacific Biosciences of California is www.pacb.com.

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 521-8000 or via email at [email protected]